INT3201

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 1978
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 11
Disease Relevance 5.12
Pain Relevance 0.56

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (F9) extracellular region (F9) plasma membrane (F9)
Anatomy Link Frequency
blood 2
plasma 2
F9 (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 4 97.44 Very High Very High Very High
Angina 10 86.16 High High
Inflammation 13 75.00 Quite High
cva 37 48.56 Quite Low
anesthesia 5 43.52 Quite Low
imagery 7 5.00 Very Low Very Low Very Low
antagonist 3 5.00 Very Low Very Low Very Low
Central nervous system 1 5.00 Very Low Very Low Very Low
tissue acidosis 1 5.00 Very Low Very Low Very Low
topical agent 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Coagulation Disorder 105 99.66 Very High Very High Very High
Hemorrhage 164 98.56 Very High Very High Very High
Pain 3 97.44 Very High Very High Very High
Pressure Volume 2 Under Development 20 94.32 High High
Injury 212 91.60 High High
Thrombosis 18 87.92 High High
Disease 8 87.52 High High
Cv General 3 Under Development 40 86.16 High High
Infection 4 85.44 High High
Disseminated Intravascular Coagulation 4 84.40 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Alternatively, the complex of factor VII, calcium, and tissue thromboplastin released from the extrinsic clotting system can also activate factor IX of intrinsic clotting system.
Positive_regulation (activate) of factor IX associated with coagulation disorder
1) Confidence 0.49 Published 2007 Journal Yonsei Medical Journal Section Body Doc Link PMC2628130 Disease Relevance 1.02 Pain Relevance 0
Triggering of the in vivo coagulation is thought to require complex formation between TF and factor VIIa to form an activation complex that converts factor IX and X into the serine proteases factor IXa and Xa, respectively.
Positive_regulation (proteases) of factor IX
2) Confidence 0.49 Published 2003 Journal Thromb J Section Body Doc Link PMC179879 Disease Relevance 0 Pain Relevance 0
Together (TF/FVIIa) they activate Factor X (FX) and Factor IX (FIX) and start the extrinsic pathway of blood coagulation.
Positive_regulation (activate) of Factor IX in blood
3) Confidence 0.34 Published 2006 Journal Thromb. Res. Section Abstract Doc Link 16378835 Disease Relevance 0.81 Pain Relevance 0.19
Together (TF/FVIIa) they activate Factor X (FX) and Factor IX (FIX) and start the extrinsic pathway of blood coagulation.
Positive_regulation (activate) of FIX in blood
4) Confidence 0.34 Published 2006 Journal Thromb. Res. Section Abstract Doc Link 16378835 Disease Relevance 0.81 Pain Relevance 0.19
This may relate to the presence of the enzyme elastase on the surface of RBC membranes, which may activate coagulation factor IX [225,226].
Positive_regulation (activate) of coagulation factor IX
5) Confidence 0.21 Published 2010 Journal Crit Care Section Body Doc Link PMC2887168 Disease Relevance 0.91 Pain Relevance 0
Bleeding episodes in five haemophiliacs with antibody to F VIII were treated by activated F IX concentrate (FEIBA).
Positive_regulation (activated) of F IX associated with coagulation disorder and hemorrhage
6) Confidence 0.11 Published 1978 Journal Acta Med Scand Section Abstract Doc Link 665313 Disease Relevance 0.38 Pain Relevance 0.10
Activated F IX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to F VIII.
Positive_regulation (Activated) of F IX
7) Confidence 0.11 Published 1978 Journal Acta Med Scand Section Title Doc Link 665313 Disease Relevance 0.37 Pain Relevance 0.09
The requirements for factor VIII (AHF) or factor IX (PTC) of hemophilic patients undergoing dental extractions were evaluated to determine the minimum effective regimen.
Positive_regulation (requirements) of factor IX
8) Confidence 0.07 Published 1984 Journal Am. J. Hematol. Section Abstract Doc Link 6421150 Disease Relevance 0.07 Pain Relevance 0
Replacement treatment is complicated by the emergence of antibodies that inhibit the activity of the injected protein.14 Approximately 20%–40% of hemophilia A patients and 2%–3% of hemophilia B patients develop inhibitors.15,16 As expected, the more profound mutations resulting in the lack of circulating FVIII or FIX are associated with higher risk of inhibitor development.17 Neutralizing or inactivating autoantibodies to FVIII may also develop in patients without a history of coagulation factor deficiency.
Positive_regulation (circulating) of FIX associated with coagulation disorder
9) Confidence 0.03 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.74 Pain Relevance 0
In addition, the AMI patients exhibited a significant elevation of plasma F XI activity, F IX concentration, and F IX activity, and vWF, fibrinogen, D-dimer, and t-PA concentrations.
Positive_regulation (elevation) of F IX in plasma
10) Confidence 0.00 Published 1992 Journal Am. J. Med. Section Body Doc Link 1466361 Disease Relevance 0 Pain Relevance 0
In addition, the AMI patients exhibited a significant elevation of plasma F XI activity, F IX concentration, and F IX activity, and vWF, fibrinogen, D-dimer, and t-PA concentrations.
Positive_regulation (elevation) of F IX in plasma
11) Confidence 0.00 Published 1992 Journal Am. J. Med. Section Body Doc Link 1466361 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox